%0 Journal Article %A Rajendra Prasad %A Abhijeet Singh %A Rahul Srivastava %A Ramawadh Singh Kushwaha %A Rajiv Garg %A Sanjeev Kumar Verma %A Giridhar Belur Hosmane %A Amita Jain %A T.G. Ranganath %T Treatment outcome of multi drug resistant tuberculosis patients in modified DOTS-PLUS: A new strategy %D 2012 %J European Respiratory Journal %P P3321 %V 40 %N Suppl 56 %X Background:-Multi Drug Resistant Tuberculosis is a global problem and growing threat to human health with notoriously difficult and challenging treatment.Aims and Objective:- To study the treatment outcome with second line drugs in patients of MDR-TB in modified DOTS-PLUS strategy.Methods: - A prospective cohort study analyzing 98 consecutive patients with MDR-TB attending the Dept of Pulmonary Medicine, CSMMU, between June 2009 to Feb 2010 with follow-up till February 2012. All the patients were given medications free of cost as per DOTS PLUS Protocol of Revised National Tuberculosis Control Programme (RNTCP). Treatment included monthly follow up, adherence check up, radiological and bacteriological assessment (sputum smear advised monthly till conversion then quarterly; culture for MTB at 0,4,6,12,18,24 months),intense health education and monitoring of adverse effects. Patients outcome considered as cure when atleast 2 of the last 3 cultures were negative and as failure when the same were positive.Results: - All the patients had resistance to at least Isoniazid and Rifampicin with mean no. of 3.02 drugs and were seronegative for HIV. Default rate and expiry rate at the completion of 24 months of treatment were observed to be 7(7.1%) and 10(10.2%) respectively. Mean smear and culture conversion time were 3.4 ± 2.1 months (1-11) and 4.6 ± 2.5 months (4-12) respectively. Sputum smear and culture conversion rate were 75/81(92.5%) and 71/81(87.7%) respectively with only 10(10.2%) patients remained culture positive. Significant side effects were experienced in only 17.4% patients.Conclusions: -Modified DOTS-PLUS strategy can be model for treatment of MDR-TB in private sector. %U https://erj.ersjournals.com/content/erj/40/Suppl_56/P3321.full.pdf